Ardelyx Inc Cash Flow Conversion Efficiency
Ardelyx Inc cash flow conversion efficiency. Based on the latest financial reports, Ardelyx Inc (ARDX) has a cash flow conversion efficiency ratio of -0.043x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.40 Million) by net assets ($149.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Ardelyx Inc (2012–2025)
Cash flow conversion efficiency of Ardelyx Inc from 2012 to 2025. This chart illustrates how Ardelyx Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Ardelyx Inc stock price for real-time trading data and today's change.
Ardelyx Inc Cash Flow Conversion Ratio Explained
Ardelyx Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Ardelyx Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ardelyx Inc ranked by their cash flow conversion efficiency. Also see market cap of Ardelyx Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
African Rainbow Capital Investments Ltd
JSE:AIL
|
0.000x |
|
Anhui Landun Photoelectron Co Ltd
SHE:300862
|
0.007x |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
0.020x |
|
Cello World Limited
NSE:CELLO
|
0.010x |
|
Yangmei Chemical Co Ltd
SHG:600691
|
-0.013x |
|
Rpmglobal Holdings Ltd
AU:RUL
|
0.126x |
|
Priortech
TA:PRTC
|
0.000x |
|
ALPHAMAB ONCOLO.DL-000002
F:3NK
|
N/A |
Annual Cash Flow Conversion Efficiency for Ardelyx Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Ardelyx Inc from 2012 to 2025. Review Ardelyx Inc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $166.95 Million | $-42.48 Million | -0.254x | +1.59% |
| 2024-12-31 | $173.29 Million | $-44.81 Million | -0.259x | +51.92% |
| 2023-12-31 | $166.82 Million | $-89.72 Million | -0.538x | +24.50% |
| 2022-12-31 | $98.33 Million | $-70.04 Million | -0.712x | +61.42% |
| 2021-12-31 | $82.62 Million | $-152.55 Million | -1.846x | -185.95% |
| 2020-12-31 | $126.11 Million | $-81.44 Million | -0.646x | -57.59% |
| 2019-12-31 | $186.66 Million | $-76.48 Million | -0.410x | +32.47% |
| 2018-12-31 | $115.81 Million | $-70.27 Million | -0.607x | -29.67% |
| 2017-12-31 | $139.31 Million | $-65.19 Million | -0.468x | +2.32% |
| 2016-12-31 | $193.15 Million | $-92.53 Million | -0.479x | +27.38% |
| 2015-12-31 | $108.90 Million | $-71.84 Million | -0.660x | -398.80% |
| 2014-12-31 | $60.68 Million | $13.40 Million | 0.221x | +189.28% |
| 2013-12-31 | $-7.32 Million | $1.81 Million | -0.247x | +98.61% |
| 2012-12-31 | $-1.24 Million | $21.98 Million | -17.769x | -- |
About Ardelyx Inc
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on… Read more